Gilead Sciences Inc.

06/10/2021 | Press release | Distributed by Public on 06/10/2021 15:06

U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C